Literature DB >> 8981331

Structural and cell-adhesive properties of three recombinant fragments derived from perlecan domain III.

B Schulze1, T Sasaki, M Costell, K Mann, R Timpl.   

Abstract

Domain III of the basement membrane proteoglycan perlecan was produced as three overlapping fragments in stably transfected mammalian cell clones. These recombinant fragments (43-48 kDa) were obtained in purified form and showed complete immunological cross-reactivity with perlecan, indicating their native structure. Rotary shadowing electron microscopy of each fragment demonstrated a small globular structure connected to a short rod. These data were interpreted to indicate that domain III has an elongated shape of 30 nm in length and consists of alternating globular domains (L4 modules) and short connecting segments attributed to tandem arrays of LE (laminin-type of EGF-like) modules which form rod-like segments in laminins. Sequence analyses of pepsin fragments were consistent with the disulfide-bonding patterns known for these modules from studies with laminin fragments, but two additional disulfide loops were also identified. Several cell lines which attached to mouse perlecan and/or human fibronectin failed to adhere to the domain III fragments, despite the fact that one of them contained an RGD (Arg-Gly-Asp) site in the L4 module. Furthermore, no significant binding was observed in solid phase binding assays with alpha 5 beta 1 and alpha v beta 3 integrins underscoring the low activity or accessibility of the RGD site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981331     DOI: 10.1016/s0945-053x(96)90138-9

Source DB:  PubMed          Journal:  Matrix Biol        ISSN: 0945-053X            Impact factor:   11.583


  8 in total

1.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

2.  Prodomains of transforming growth factor beta (TGFbeta) superfamily members specify different functions: extracellular matrix interactions and growth factor bioavailability.

Authors:  Gerhard Sengle; Robert N Ono; Takako Sasaki; Lynn Y Sakai
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

3.  Perlecan displays variable spatial and temporal immunolocalisation patterns in the articular and growth plate cartilages of the ovine stifle joint.

Authors:  James Melrose; Susan Smith; Martin Cake; Richard Read; John Whitelock
Journal:  Histochem Cell Biol       Date:  2005-06-17       Impact factor: 4.304

4.  Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Authors:  Margaret M French; Ronald R Gomes; Rupert Timpl; Magnus Höök; Kirk Czymmek; Mary C Farach-Carson; Daniel D Carson
Journal:  J Bone Miner Res       Date:  2002-01       Impact factor: 6.741

5.  Complex patterns of alternative splicing mediate the spatial and temporal distribution of perlecan/UNC-52 in Caenorhabditis elegans.

Authors:  G P Mullen; T M Rogalski; J A Bush; P R Gorji; D G Moerman
Journal:  Mol Biol Cell       Date:  1999-10       Impact factor: 4.138

6.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

Review 7.  The role of heparan sulphate in development: the ectodermal story.

Authors:  Vivien Jane Coulson-Thomas
Journal:  Int J Exp Pathol       Date:  2016-07-06       Impact factor: 1.925

8.  Exome sequencing identifies a rare HSPG2 variant associated with familial idiopathic scoliosis.

Authors:  Erin E Baschal; Cambria I Wethey; Kandice Swindle; Robin M Baschal; Katherine Gowan; Nelson L S Tang; David M Alvarado; Gabe E Haller; Matthew B Dobbs; Matthew R G Taylor; Christina A Gurnett; Kenneth L Jones; Nancy H Miller
Journal:  G3 (Bethesda)       Date:  2014-12-12       Impact factor: 3.154

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.